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Defects in perforin lead to the failure of T and NK cell 
cytotoxicity, hypercytokinemia, and the immune dys-
regulatory condition known as familial hemophagocytic 
lymphohistiocytosis (FHL). The only curative treatment 
is allogeneic hematopoietic stem cell transplantation 
which carries substantial risks. We used lentiviral vectors 
(LV) expressing the human perforin gene, under the tran-
scriptional control of the ubiquitous phosphoglycerate 
kinase promoter or a lineage-specific perforin promoter, 
to correct the defect in different murine models. Follow-
ing LV-mediated gene transfer into progenitor cells from 
perforin-deficient mice, we observed perforin expression 
in mature T and NK cells, and there was no evidence 
of progenitor cell toxicity when transplanted into irra-
diated recipients. The resulting perforin-  reconstituted 
NK cells showed partial recovery of cytotoxicity, and 
we observed full recovery of cytotoxicity in polyclonal 
CD8+ T cells. Furthermore, reconstituted T cells with 
defined antigen specificity displayed normal cytotoxic 
function against peptide-loaded targets. Reconstituted 
CD8+ lymphoblasts had reduced interferon-γ secretion 
following stimulation in vitro, suggesting restoration of 
normal immune regulation. Finally, upon viral challenge, 
mice with >30% engraftment of gene-modified cells 
exhibited reduction of cytokine hypersecretion and cyto-
penias. This study demonstrates the potential of hema-
topoietic stem cell gene therapy as a curative treatment 
for perforin-deficient FHL.
Received 10 September 2014; accepted 6 December 2014; advance online   
publication 20 January 2015. doi:10.1038/mt.2014.242
INTRODUCTION
Hemophagocytic lymphohistiocytosis (HLH) represents a spec-
trum of inherited and acquired conditions characterized by 
severe immune dysregulation.1 The inherited form is termed 
familial hemophagocytic lymphohistiocytosis (FHL) and arises 
from genetic defects that lead to abnormalities of T and NK cell 
cytotoxicity that in turn result in hypercytokinemia, macrophage 
activation, hemophagocytosis and a clinical syndrome of fever, 
coagulopathy, hepatosplenomegaly, and often central nervous 
system involvement.2 Five different genetic loci have now been 
identified (FHL 1–5), and of these, perforin deficiency (FHL-2) is 
the most common and best characterized.3
In viral infections, effector T and NK cells form an immuno-
logical synapse with virally infected target cells. Within the syn-
apse, there is exocytosis of specialized granules that mediate cell 
cytotoxicity. Perforin is contained within these granules and upon 
release forms pores in target cell membranes, allowing the passage 
of granzymes which initiate apoptotic pathways, eventually lead-
ing to target cell death.4 Mutations in the perforin gene (PRF) lead 
to failure of pore formation and target cell cytotoxicity in effec-
tor cells, resulting in proliferation of highly activated cytotoxic 
T and NK cells, which in turn lead to hypercytokinemia and the 
subsequent clinical sequelae of HLH. A murine perforin-deficient 
model of HLH has been generated which accurately recapitulates 
the immunological characteristics of the disease.5 Correction of 
immune dysregulation in this model by transplantation with wild-
type (WT) bone marrow has been demonstrated, and in these 
studies, the prevention of HLH development is critically depen-
dent upon the engraftment of functional CD8+ T cells.6
The prognosis for FHL patients is poor with a median survival of 
less than 2 months after diagnosis if untreated.7 Treatment of FHL-2 
is currently limited to the control of infectious triggers and chemo-
therapeutic regimes to control immune dysregulation, but ~20% 
of patients do not respond and die as a result of ongoing HLH.7,8 
The disease can only be corrected by allogeneic hematopoietic stem 
cell transplantation. Overall survival is best when a matched donor 
is available and the patient is in clinical remission,9 but even then, 
survival rates vary from 70 to 90% depending on the conditioning 
regime used.10,11 Following mismatched transplants or in patients 
who are transplanted with active HLH, the outcome following 
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hematopoietic stem cell transplantation is considerably worse with 
~50% survival.7 The development of alternative strategies based on 
gene transfer may have significant benefit.
Gene therapy using viral vector–mediated gene transfer into 
autologous HSCs has been shown to be curative in a number 
of severe monogenic immunodeficiencies.12–16 However, such 
approaches of “additive” gene transfer have not been attempted 
for conditions of immune dysregulation, such as HLH, which are 
substantially different than disorders of immune development, 
such as severe combined immune deficiency. Based on our results 
showing that 10–20% WT hematopoietic chimerism is sufficient 
to reestablish normal immune regulation,6 we investigated the fea-
sibility of HSC gene therapy for perforin deficiency. In this report, 
we show that gene transfer using self-inactivating lentiviral vec-
tors (LVs) results in expression of perforin in T and NK cells and 
leads to a significant correction of the cytotoxic defects both in 
vitro and in vivo in murine models of HLH. Our results suggest 
that gene therapy may be a promising therapeutic approach for 
perforin-deficient FHL.
RESULTS
LV construction for FLH gene therapy
Two self-inactivating LVs were constructed to promote expression of 
the human perforin cDNA and GFP under the transcriptional con-
trol of either the human phosphoglycerate kinase (PGK) promoter 
or a lineage-specific human perforin promoter (PRFprom) (PGK.
PRF and PRF.PRF; Figure 1). A control vector (PGK.GFP) which 
only expresses GFP and a second control expressing a mutant per-
forin with null function (PGK.PRFmut) were also generated. The 
full human PRF promoter is comprised of three regions that span 
a total of ~5.1 Kb on human chromosome 10 (ref. 17). For this vec-
tor, a fragment of this promoter was used consisting of 1.3 Kb DNA 
upstream of the human perforin gene, which contains the basal core 
promoter (−244 bp), for expression in effector cells and two ele-
ments at −350 and −650 bp that repress transcriptional activity in 
 noneffector  cells.18 The two functional perforin-expressing vectors 
(PGK.PRF and PRF.PRF) were tested for expression of GFP and per-
forin in human cell lines, and high levels of expression were observed 
in all cell lines using the PGK promoter–driven vector, while expres-
sion from the vector with PRFprom was restricted to T (Jurkat) and 
NK (YT) cell lines (Supplementary Figure S1). These results were 
observed 5 days after transduction and further confirmed 15 days 
after transduction.
To test for normal perforin expression and processing in a 
perforin-deficient cell line, we transduced the RBL-1 cell line (rat 
basophilic leukemia) which is able to process and deliver perforin 
to secretory granules. Perforin expressed from the PGK.PRF vec-
tor exhibited the correct conformation of precursor and mature 
forms typically noted in lysates from NK and CTL (YT shown for 
comparison,  Supplementary Figure S2a). Perforin expression 
was localized in secretory granules around the cell membrane 
similar to that seen in YT cells (Supplementary Figure S2b).
Restoration of cytotoxicity in vitro
To determine if perforin gene transfer could restore cytotoxic 
function in primary effector cells, splenic NK and T cells derived 
Figure 1  Schematic representation of self-inactivating perforin lenti-
viral vectors (LV). Plasmid configuration is shown. Δ marks SIN deletion 
with partially deleted U3 of 3′ long terminal repeat. ppt, central poly-
purine tract; SD/SA, splice donor/splice acceptor; ψ, packaging signal; 
PGK, phosphoglycerate kinase promoter; PRF, perforin promoter; IRES, 
internal ribosomal entry site; WPRE, woodchuck hepatitis virus posttran-
scriptional regulatory element; U3/R/U5, LTR elements.
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Figure 2 Perforin reconstitution in peripheral NK and T cells leads to 
restoration of cytotoxic function. NK and CD8+ T cells from prf−/− mice 
were transduced with PGK.GFP, PGK.PRF, or with PRF.PRF vectors and 
processed for chromium assays. (a)  51Cr release from RMA-S cells co-
incubated with transduced and untransduced NK cells and WT mice NK 
cells. (b) 51Cr release from anti-CD3 bound P815 cells co-incubated with 
transduced and untransduced CD8+ T cells and WT mice CD8+ T cells. 
The effector to target ratios were normalized taking into consideration 
the percentage of GFP-positive effector cells (7% in NK cells and 10% 
in CD8+ T cells with both PRF vectors). The P values correspond to both 
the comparisons between the PGK.PRF and the PRF.PRF groups with the 
prf−/− group. The results presented show one representative experiment 
from a series of three experiments, and the error bars represent the SEM 
from the chromium assay triplicates.
Primary NK cells
40
Prf−/−
a
b
PGK.GFP
PGK.PRF
PRF.PRF
WT
Prf
−/−
PGK.GFP
PGK.PRF
PRF.PRF
WT
30
20
%
 
5
1
C
r
 
r
e
l
e
a
s
e
%
 
5
1
C
r
 
r
e
l
e
a
s
e
10
0
40
10:1
P < 0.05
P < 0.005
P < 0.001
P < 0.001
Effector/target ratio
5:1 2:5:1 1:3:1
30
20
10
0
1.25:1 0.63:1
Effector/target ratio
Primary CD8
+ T cells
0.31:1 0.16:1
738  www.moleculartherapy.org  vol. 23 no. 4 apr. 2015© The American Society of Gene & Cell Therapy
Gene Therapy for Perforin Deficiency
from perforin-deficient mice (prf−/−) were transduced with either 
the PGK.PRF or PRF.PRF vector. Despite low levels of transduc-
tion (GFP expression < 10% with copy numbers of 3 for PGK.
GFP, 2.5 for PGK.PRF, and 2 for PRF.PRF), almost full recovery 
of CD8+ T-cell cytotoxicity (redirected killing of P815 cells con-
jugated with anti-CD3 antibody) was obtained with both vectors 
when normalized to the number of GFP-positive cells (Figure 2b) 
and recovery of NK cell cytotoxicity to 40–50% of normal was 
observed (Figure 2a). Thus, both vectors were able to restore cyto-
toxic activity in primary murine perforin-deficient peripheral T 
and NK cells.
LV gene transfer into HSCs from perforin-deficient 
mice
HSC reconstitution of prf−/− mice with lentiviral gene therapy was 
performed transducing Lin-Sca-1+c-kit+ cells (LSK) with either 
the PGK.PRF or PRF.PRF or the control PGK.GFP vector. The 
transduction efficiency obtained using the PGK.PRF, by GFP 
expression, was 36 and 7% with the PRF.PRF with the same copy 
number of 0.5 (Figure 3a,b). This result demonstrates that despite 
equivalent levels of vector integration, the PRF promoter shows 
limited expression in progenitor cell lineages (Figure 3a,b).
HSC perforin gene transfer does not affect 
progenitor cell commitment or immune cell 
development
To assess the risk of toxicity associated with the potential expres-
sion or overexpression of perforin in progenitor cells, we inves-
tigated the progenitor cell function of transduced LSK cells. The 
viability of the transduced cells before injecting into mice was 
above 90% for all three vectors used (PGK.PRF or PRF.PRF or 
the control PGK.GFP; data not shown). Transduced and untrans-
duced cells were used in hematopoietic colony formation assay 
(Figure 3c), and the number and type of hematopoietic colonies 
formed was not impaired following transduction by PGK.PRF or 
PRF.PRF vectors in comparison to untransduced cells or PGK.
GFP transduced cells and suggests that perforin expression does 
not compromise progenitor cell activity.
Three months after injecting mice with gene-corrected cells, 
the analysis of the blood, thymus, and spleen showed that all mice 
had normal numbers of NK cells, T cells, B cells, and granulocytes 
in comparison with WT mice and prf−/− mice (Supplementary 
Figure S3), suggesting that transduction of hematopoietic stem 
cells with PGK.PRF or PRF.PRF perforin expressing vectors does 
not inhibit the development of different immune cell lineages.
HSC gene transfer leads to transgene expression in 
peripheral cells
The analysis of GFP expression shows that transduction of LSK 
cells with PGK.PRF leads to GFP expression in all hematopoietic 
tissues, between 20% in the bone marrow and 50% in the thy-
mus (Supplementary Figure S4a). The expression of GFP in mice 
reconstituted with the PRF.PRF was higher in CD8+ T cells and 
NK cells, isolated from the spleen and stimulated in culture, con-
firming preferential expression in effector cells with this promoter 
(Supplementary Figure S4b). For both the PGK.PRF and the 
PRF.PRF groups, the average copy number in NK cells and CD8+ 
T cells was 0.4, while in the PGK.GFP group, this copy number 
was 2.5. Following transduction of LSK cells with either PGK.
PRF or PRF.PRF and in contrast to the levels of GFP, the detection 
Figure 3 Efficient lentiviral vector transduction of progenitor cells and demonstration of normal colony formation from transduced cells. 
(a) Flow cytometry plots showing GFP expression in LSK cells transduced with PGK.GFP, PGK.PRF, or PRF.PRF. (b) Transduction efficiency and viral 
copy number of the LSK cells transduced with PGK.GFP, PGK.PRF, and PRF.PRF. (c) The same cells were used in a hematopoietic colony formation 
assay: BFU-E, burst forming unit erythroid; CFU, colony forming unit granulocyte macrophage; CFU-GEMM, colony forming unit granulocyte, ery-
throid, macrophage, megakaryocyte. The results presented show one representative experiment from a series of three experiments, and the error 
bars represent the SEM from the colony formation assay triplicates.
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of perforin by flow cytometry was low in all cells except NK 
(Supplementary Figure S4a,b and Figure 4d). Figure 4d shows 
the perforin staining in NK cells of one representative sample of 
the PGK.PRF and the PRF.PRF groups. This finding likely reflects 
the lack of secretory granules required for efficient perforin traf-
ficking and storage in all cells except TCR-stimulated CD8+ T 
cells (CTL) and NK cells.
HSC perforin gene transfer restores T and NK cell 
cytotoxic function and inhibits IFN-γ secretion in vitro
The major defect caused by perforin deficiency as demonstrated 
by the prf−/− model is the inability of T and NK cells to kill tar-
get cells.19 Approximately 3 months following gene modified 
LSK cell transfer, NK and CD8+ T cells were isolated from the 
spleens of the reconstituted mice and expanded and activated in 
Figure 4 Lentiviral vector–mediated HSC perforin gene transfer restores T and NK cell cytotoxic function and reduces IFN-γ secretion by 
T lymphoblasts in vitro. (a)  51Cr release from RMA-S cells co-incubated with NK cells from mice reconstituted with LSK cells transduced with 
PGK.GFP, PGK.PRF, and PRF.PRF, prf−/− and WT mice. (b) 51Cr release from anti-CD3 bound P815 cells co-incubated with CD8+ T cells from mice 
reconstituted with LSK cells transduced with PGK.GFP, PGK.PRF, and PRF.PRF, prf−/− and WT mice. The P values correspond to both the comparisons 
between the PGK.PRF and the PRF.PRF groups with the PGK.GFP group. The highest P value is shown for each point. (c) IFN-γ production by CD8+ 
lymphoblasts derived from prf−/− mice reconstituted with LSK cells transduced with PGK.GFP, PGK.PRF, and PRF.PRF, from prf−/− and from WT mice 
after co-incubation with anti-CD3–bound P815 cells for 4 hours. For the three assays n = 3 for each group, and the error bars represent the SD. (d) 
Representative flow cytometry dot plots for perforin expression in NK cells from one prf−/− mouse, one mouse reconstituted with PGK.PRF, and one 
mouse reconstituted with PRF.PRF.
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culture for 5 and 3 days, respectively, prior to testing cytotoxic 
function by chromium release assays. In both PGK.PRF and 
PRF.PRF reconstituted mice, the reconstitution of NK cell cyto-
toxicity was 40% of that seen in WT cells (Figure 4a), whereas 
the recovery of CD8+ T cell cytotoxicity (redirected killing of 
P815 cells conjugated with anti-CD3 antibody) was similar to 
that seen in WT cells (Figure 4b).
Hypercytokinemia is a major feature of the prf−/− model, and 
the development of HLH disease symptoms is driven by an ele-
vated production of IFN-γ by activated perforin-deficient CD8+ 
T cells in vivo.5 As a surrogate for in vivo challenge, CD8+ lym-
phoblasts cultured from the spleens of the reconstituted mice 
were used in an IFN-γ assay where the cells were co-incubated 
with target cells loaded with anti-CD3 antibody. After 4 hours, 
the supernatant was removed and IFN-γ measured by enzyme 
linked immunosorbent assay (Figure 4c). CD8+ lymphoblasts 
from prf−/− mice exhibit high levels of IFN-γ production. In con-
trast, perforin-reconstituted CD8+ T cells showed significantly 
reduced IFN-γ, with the cells from mice reconstituted with PRF.
PRF transduced cells showing a reduction to levels very similar to 
that seen in WT cells.
These results demonstrate that the progenitor cell reconstitu-
tion of prf−/− mice with perforin expressing LVs leads to a recovery 
of CD8+ lymphoblast function in vitro, both in perforin-mediated 
killing and regulation of IFN-γ secretion. We have observed stable 
recovery of cytotoxic function in cells from mice which have been 
engrafted long term (>6 months) with gene-corrected hematopoi-
etic progenitors (data not shown).
HSC perforin gene transfer corrects antigen-specific 
CD8+ T-cell cytotoxicity in P14 TCR transgenic, prf−/− 
deficient mice
We next measured antigen-specific CTL function utilizing mice 
which were perforin deficient and also transgenic for a T-cell recep-
tor specific for the lymphocytic choriomeningitis virus (LCMV)-
derived GP33 epitope presented in the context of Db (P14.prf−/−) as 
donor mice for HSC transplantation. HSC from P14.prf−/− mice were 
transduced with PGK.PRF, or a mutated PRF protein (PRFmut) 
under the control of the PGK promoter (PGK.PRFmut). PRFmut has 
a missense mutation (PRF-T435M) that causes a postsynaptic defect 
in lipid binding allowing protein secretion but not binding of target 
cells.20 LSK transduction efficiencies were equivalent with both vec-
tors (55 and 45% for the PGK vectors expressing WT human PRF or 
PRFmut, as assessed by GFP expression, data not shown, with copy 
numbers of 7 and 13, respectively).
After stimulation with gp33 peptide for 48 hours and expan-
sion of splenocytes in IL-2 for 3–4 days, cytotoxicity was evalu-
ated against gp33-loaded EL4 target cells. GFP expression in CTL 
was similar in both WT human PRF and PRFmut expressing mice 
(ranging from 19 to 44%), and perforin expression was detectable 
in the CTL of both cohorts (Figure 5a). Overall, we see less pro-
tein in lines expressing PRFmut because of misfolding.20 Antigen-
specific cytolysis of targets was detected from gene corrected, CTL 
expressing WT PRF but not CTL expressing PRFmut (Figure 5b). 
In these gene-corrected CTL, function was equivalent to CTL 
generated similarly from nontransplanted, perforin sufficient, P14 
transgenic mice (P14.WT). Taken together, these data show that 
gene transfer of a PRF gene into prf−/− HSC can restore cytotoxic-
ity in CTLs recognizing a specific viral antigen.
HSC perforin gene transfer partially corrects disease 
phenotype of LCMV-infected prf−/− mice
Optimal assessment of functional gene correction for perforin 
deficiency requires in vivo testing in the setting of a viral challenge. 
Therefore, we transduced bone marrow LSK cells from prf−/− mice 
with PGK.PRF, PGK.PRFmut, and PRF.PRF and reconstituted 
irradiated prf−/− mice. WT murine LSK cells were transplanted as 
a positive control, expressing endogenous murine perforin. After 
waiting 16 weeks for optimal immune reconstitution, we chal-
lenged these animals with LCMV infection. After LCMV chal-
lenge, prf−/− mice develop marked elevation of serum IFN-γ levels, 
compared to WT animals, which leads to severe cytopenias, pros-
tration, and death in most animals within 3 weeks. As expected, 
we observed that prf−/− mice reconstituted with marrow expressing 
mutant (nonfunctional) perforin displayed much higher IFN-γ 
Figure 5 Lentiviral vector–mediated HSC perforin gene transfer 
restores PRF expression and corrects antigen-specific CTL killing in 
prf−/− mice. LV vectors encoding either wild-type human PRF or a mutant 
human PRF (PRFmut) under the PGK promoter were used to transduce 
LSK cells from P14.prf−/− mice, which were transplanted into irradiated 
prf−/− recipients. (a) CTL lines derived from these mice were analyzed for 
GFP expression by flow cytometry, and data is listed as %GFP above the 
western blot. Perforin expression was analyzed by western blot using 
Δ G9 anti-perforin Ab. Samples from gene-transduced P14.prf−/− mice 
were compared to P14.WT and P14.prf−/− mice. (b)  51Cr release from 
GP33-loaded EL4 target cells co-incubated with CTL from mice reconsti-
tuted with PGK.PRF (n = 3) or with PGK.PRFmut (n = 3), P14.WT (n = 5), 
and P14.prf−/− mice (n = 3).
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levels than those reconstituted with WT marrow. In comparison 
to animals reconstituted with mutant perforin (PGK.PRFmut), we 
observed that animals with ≥30% chimerism of perforin gene-cor-
rected cells (either PGK.PRF or PRF.PRF, ranging from 33 to 92%, 
with a median chimerism of 72 and 47%, respectively) showed 
partial restoration of antigen-specific CTL killing and displayed 
significantly lower serum IFN-γ levels (Figure 6a,b). In addition, 
mice reconstituted with functional perforin displayed a signifi-
cantly decreased drop in hemoglobin and platelet levels in com-
parison to mice reconstituted with mutant perforin (Figure 6c,d), 
suggesting that perforin gene transfer can at least partially prevent 
the cytopenias seen in virally driven HLH. Consistent with previ-
ously published data,6 animals with less than 30% gene-corrected 
chimerism did not display a clear trend toward correction of 
IFN-γ or other indices (data not shown). Because these animals 
were a small portion of all recipients (less than 1/3 of transplanted 
animals), we were not able to define a threshold of benefit more 
precisely. This initial proof-of-principle study demonstrates the 
feasibility of significantly improving immune regulation via len-
tiviral delivery of the perforin gene to HSCs. Further longer term 
studies including formal survival experiments are required for 
definitive confirmation of this approach.
DISCUSSION
FHL-2 is a devastating inherited disorder of childhood caused 
by mutations in the perforin gene. Current treatment options 
for this disease are limited, and permanent correction is cur-
rently only possible with hematopoietic stem cell transplanta-
tion. Hematopoietic stem cell gene therapy offers an alternative 
approach, and the present study shows that correction of the gene 
defect by lentiviral gene transfer into autologous HSCs leads to 
rescue of peripheral CD8+ T-cell cytotoxicity, partial rescue of NK 
cell cytotoxicity, and reversal of dysregulated IFN-γ secretion by 
CD8 T lymphoblasts in vitro.
Two lentiviral constructs containing either the PGK promoter 
or an endogenous perforin promoter, PRFprom, were tested in 
this study. Our expression data in RBL cells, which are able to 
process perforin, suggests that following gene transfer from these 
vectors, perforin is expressed, modified, and located in a similar 
way to perforin in WT cells.
The use of the PRFprom was designed to restrict perforin 
expression to mature T and NK cells and inhibit expression in 
stem cells where ectopic perforin expression may have unwanted 
side effects. The pattern of expression in a number of different cell 
lineages demonstrates the specificity of this promoter. While the 
PGK promoter was able to promote expression in all cell lines, the 
PRFprom was only active in the Jurkat T cell line and in the YT 
NK cell line (Supplementary Figure S1). The complete human 
perforin promoter region consists of 5.1 Kb and is composed of 
multiple sets of positive and neutral elements.18 For the construc-
tion of this vector, we used only a small portion of the endogenous 
promoter that included two repression sites (present −350 and 
Figure 6 Perforin gene correction partially restores antigen-specific CTL killing and rescues prf−/− mice from the development of HLH-like 
disease after LCMV infection. Prf−/− mice were irradiated and reconstituted with WT marrow or prf−/− LSK transduced with PGK.PRF, PGK.PRFmut, 
or PRF.PRF. After 16 weeks, animals were challenged with LCMV infection. (a) On day 8 following infection, splenocytes were tested for cytotoxic 
function by 51Cr release assay using GP33-loaded EL4 target cells. Error bars represent SD from four mice/group. (b) Day 8 serum IFN-γ levels from 
animals with ≥30% chimerism of gene corrected (or WT) cells are displayed (n =10–19/group, from three experiments). (c,d) Blood hemoglobin and 
platelet counts were assessed in animals (with ≥30% gene-corrected chimerism) on day 15 after infection (n = 7–9/group, except PGK.PRFmut where 
n = 2 due to early deaths, assessed across two experiments).
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−650 bp upstream the perforin gene) and the basal core promoter 
(present −244 bp upstream the perforin gene). The perforin pro-
moter sequence used here does not contain cis-acting sequences 
that specifically enhance killer-lymphocyte transcription21 and are 
present in the full endogenous promoter sequence. Thus, further 
improvement of expression with this promoter is still possible 
with the addition of these sequences that enhance transcription.
The use of a specific lineage restricted promoter may offer 
safety benefits by avoiding perforin expression in stem cell and 
progenitor lineages. However, despite these concerns, in our stud-
ies, when perforin was expressed under the control of the ubiqui-
tous PGK promoter in LSK cells, we did not observe any obvious 
adverse consequences in terms of progenitor colony formation 
or lineage commitment and development when compared to use 
of the PRF promoter that shows inhibition of expression in stem 
cells (Figure 3c and Supplementary Figure S3). Furthermore, 
the expression of perforin following PGK promoter progeni-
tor cell transduction was still higher in activated T and NK cells 
in comparison to other peripheral cell types, as observed by the 
overall level of perforin expression in all tissues (Supplementary 
Figure  S4). In the WT situation, transcriptional control and 
restriction of expression is provided mainly by a specific pro-
moter18,21,22; however, other posttranscriptional mechanisms23,24 
and posttranslational modifications also play a part in perforin 
expression.25 These studies confirm that there is a requirement for 
posttranscriptional/translational modification that is found only 
in T and NK cell lineages favoring the expression in these lineages 
even when the PGK promoter is used.
The PGK promoter has now been used in the context of self-
inactivating LV vectors in a clinical trial of HSC gene therapy for 
metachromatic leukodystrophy with considerable efficacy26 and 
may have advantages for other hematopoietic diseases. If further 
studies suggest that high levels of stem cell expression of perforin 
is undesirable, then approaches such as the use of miRNA target 
sites that de-target perforin expression in stem cells could be used 
in conjunction with the PGK promoter in LV vectors.27,28
The fundamental defect in perforin deficiency is the failure 
of effector cell cytotoxicity that ultimately leads to hypercytokin-
emia and macrophage activation. In this study, we were able to 
show that effector cell correction following either peripheral or 
progenitor cell transduction led to recovery of cytotoxic function 
in both CD8+ T and NK cells (Figures 2 and 4). Interestingly, in 
CD8+ T cells, the level of recovery was complete and comparable 
to WT, while only partial correction was seen in NK cells despite 
equivalent levels of gene transfer in both cell lineages. Utilizing 
P14 TCR transgenic prf−/− mice, we also demonstrated reconstitu-
tion of CD8+ T cell cytotoxicity against antigen-specific targets 
(Figure 5). The ability of restored perforin cytotoxicity to correct 
dysregulated IFN-γ secretion was demonstrated by the decreased 
IFN-γ production seen in PRF expressing CD8+ lymphoblasts 
when stimulated with anti-CD3 bound P815 targets (Figure 4c).
The reasons for the discrepancy in restoration of CD8 and 
NK cell killing are not clear, but previous studies have shown the 
importance of the CD8 population in controlling HLH. Indeed, 
murine and human transplant studies suggest that even low lev-
els (~20%) of WT donor T-cell chimerism is sufficient to prevent 
HLH relapse29 and in the murine model protects against LCMV 
induced HLH.6 Thus, the engraftment of relatively low levels of 
functional gene corrected T cells could lead to significant clini-
cal benefit. The extrapolation of this model to the clinical set-
ting would be transduction of autologous CD34+ cells which 
are then reinfused into a conditioned host. The major advan-
tage of this approach over allogeneic hematopoietic stem cell 
transplantation is the lack of graft-versus-host disease which 
is a significant complication in both matched and mismatched 
transplants. In addition, the safety of an autologous gene ther-
apy procedure albeit with cytoreductive chemotherapy has been 
illustrated by the excellent 1 year survival in a number of gene 
therapy studies for Wiskott–Aldrich syndrome, chronic granu-
lomatous disease, adrenoleukodystophy, and metachromatic 
leukodystrophy.16,26,30,31
Previous studies have shown how HLH may develop in prf−/− 
mice after infection with LCMV.5 The features of HLH in the 
murine system accurately recapitulate human disease and include 
significant immune dysregulation with hypercytokinemia, mac-
rophage activation, and cytopenias. In a viral infection such as 
LCMV, the CD8+ T cell cytotoxic and IFN-γ responses are vig-
orous, and the potential for immune-mediated pathology is sub-
stantial. We have challenged reconstituted mice with LCMV to 
ascertain if this gene correction approach will allow protection 
in vivo. In these experiments, we demonstrate that antigen-specific 
restoration of CTL killing is partially restored and hypersecretion 
of IFN-γ and the severity of cytopenias were significantly reduced, 
compared to untreated prf−/− mice. The correction seen was partial 
but nevertheless significant. This level of correction was only seen 
in mice that had >30% gene-corrected cells. Together, these data 
suggest that full correction may require either higher number of 
engrafted, gene-modified cells and/or maximal perforin expres-
sion from gene corrected cells. Further studies are ongoing to 
address these issues, but these initial results provide encouraging 
data to support this approach.
Overall, this study demonstrates for the first time the potential 
for HSC gene therapy to correct an immune dysregulatory con-
dition and rescue the functional defects associated with perforin 
deficiency. This can be achieved to a significant degree with the use 
of either an endogenous PRF promoter or a ubiquitous promoter 
such as PGK. The concept of using HSC gene transfer to correct 
immune developmental or function defects has been verified in 
other models32 but has not been tested for immune dysregulatory 
conditions. Perforin defects compose 30–40% of all genetic causes 
of FHL. We are aware of other projects that are developing gene 
therapy for defects in munc 13–4 which is the other major genetic 
cause of FHL (Cavazzana, personal communication), and thus, it 
is possible that in time a gene therapy option may be available for 
the majority of patients affected by FHL.
MATERIALS AND METHODS
Vector construction. The steps involved in vector construction are 
described in Supplementary Materials and Methods.
Mice. Perforin-deficient mice (prf−/−) were obtained from the Jackson 
Laboratory (Bar Harbor, ME) strain C57BL/6-Prf1tm1Sdz/J. All experi-
ment procedures were approved by the Institutional Research Ethics 
Committee (Institute of Child Health, University College London, UK) 
and performed according to UK Home Office Animal Welfare Legislation. 
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Murine studies at Cincinnati Children’s Hospital Medical Center were con-
ducted in accordance with Cincinnati Children’s Hospital Medical Center 
approved protocol.
Primary cells. Mouse primary NK cells were isolated from spleens of 
prf−/− mice using CD49b (DX5) microbeads (Miltenyi Biotec, Woking, 
UK) following the manufacturer instructions. The cells were cultured in 
RPMI medium with 10% fetal calf serum, 1% Pen/Strep, 1 mmol/l 2-mer-
captoethanol (Invitrogen), 1 mmol/l sodium pyruvate (Invitrogen), and 
1000 U/ml IL-2 (Peprotech, Rocky Hill, NJ). Mouse primary CD8+ T cells 
were isolated from spleens of prf−/− mice using CD8a (Ly-2) microbeads 
(Miltenyi Biotec) following the manufacturer’s instructions. The cells were 
cultured in RPMI medium with 10% fetal calf serum, 1% Pen/Strep, 1 
mmol/l 2-mercaptoethanol, 1 mmol/l sodium pyruvate, 30 U/ml IL-2, and 
1 µg/ml anti-CD3 antibody (BD Biosciences, Oxford, UK). Both NK and 
CD8+ T cells were transduced by two rounds of spinoculation with vec-
tors at an MOI of 50 at 1,800 g for 45 minutes at room temperature. After 
72 hours, GFP expression was analyzed by flow cytometry, and cells were 
processed for cytotoxicity assays. The results presented show one represen-
tative experiment from a series of three experiments.
Transduction and transplantation of LSK cells. Bone marrow cells were 
harvested from the femurs and tibias of prf−/− mice, and the lineage negative 
(lin-ve) progenitors were isolated using a lineage cell depletion kit (Miltenyi 
Biotec). Lin-ve cells were blocked with 2.4 G antibody (BD Bioscience) for 
15 minutes and then stained with streptavidin-fluorescein isothiocyanate, 
PE Ly-6A/E (Sca-1), and APC CD117 (c-kit; all from BD Biosciences) 
and sorted for the lin-sca-1+c-kit+ population (LSK cells) and the lin-
sca-1-c-kit- population (L-S-K- cells) in a MoFlo XDP sorter (Beckman 
Coulter, Miami, FL). The LSK population was prestimulated overnight in 
StemSpan SFEM serum-free medium (StemCell Technologies, Grenoble, 
France) supplemented with 1% fetal bovine serum, 1% penicillin strep-
tomycin, 100 ng/ml mSCF, 100 ng/ml mFLT-3L, and 20 ng/ml hTPO (all 
from Peprotech) and transduced at a MOI of 50 with the perforin vectors 
twice within a 12-hour interval. Transduced cells were harvested on the 
next day, and 2 × 104 transduced LSK cells together with 4 × 104 L-S-K- irra-
diated cells (cultured in the transduction medium in parallel) were injected 
intravenously into the tail veins of lethally irradiated (6 Gy first day and 4 
Gy second day) prf-/- mice. Transduced LSK cells (2 × 104) were left in cul-
ture, and 72 hours after transduction, GFP expression was analyzed by flow 
cytometry, and 1 week after transduction, cells were treated with benzo-
nase and used to determine vector copy number. After 12 weeks, mice were 
sacrificed, and blood, bone marrow, thymus and spleen were removed for 
each mouse for analysis. From the spleens, NK cells and CD8+T cells were 
isolated and cultured as described in the Primary Cells section. NK cells 
and CD8+T cells were maintained in culture for 5 and 3 days, respec-
tively and used for perforin intracellular staining and cytotoxicity assays. 
CD8+T cells cultured for 3 days were also used in an IFN-γ assay.
The reconstitution results presented in Figure 4 show one 
representative experiment (experiment 2) from a series of three 
experiments where three mice were corrected with PGK.PRF and three 
mice were corrected with PRF.PRF transduced cells, the results from 
experiments 1 and 3 are shown as Supplementary Figures S5 and S6. 
A similar protocol was followed for the P14.prf−/− LSK reconstitutions.
51Cr release cytotoxicity assay and IFN-γ assay. For NK cell cytotoxic-
ity, NK cells and 51Cr labeled RMA-S target cells (5 × 103) were mixed in 
96-well round bottom plates at various effector/target ratios and incubated 
for 4 hours at 37 °C. For CD8+ T-cell redirected killing assay, CD8+ T 
cells conjugated with anti-CD3 and 51Cr labeled P815 target cells were 
mixed in 96-well round bottom plates at various effector/target ratios and 
incubated for 4 hours at 37 °C. For antigen-specific CTL function, P14.
prf−/− splenocytes were stimulated in vitro with GP33 antigen for 48 hours 
and expanded 3 more days in IL-2 to generate CTL. The CTL were co-
incubated with EL4 target cells labeled with GP33 and 51Cr in 96-well V 
bottom plates at various effector/target ratios and incubated 4 hours at 37 
°C. For antigen-specific CTL function, CTLs were isolated from the spleens 
of mice 8 days after LCMV challenge. The CTLs were co-incubated with 
EL4 target cells labeled with GP33 and 51Cr in 96-well V-bottom plates at 
various effector/target ratios and incubated 4 hours at 37 °C. The release 
of 51Cr in the supernatant was measured with a γ-counter. All assays were 
done in triplicate.
For IFN-γ assay, 1 × 105 CD8+ lymphoblasts labeled with 1 μg/ml 
anti-CD3, and 5 × 103 P815 target cells were mixed in 96-well round 
bottom plates and incubated for 4 hours at 37 °C. The concentration of 
IFN-γ was determined by using enzyme linked immunosorbent assay kit 
obtained from R&D Systems (Minneapolis, MN) per the manufacturer’s 
instructions.
In vivo LCMV challenge. Prf−/− mice were injected with lentivirally trans-
duced LSKs (2.5–5.0 × 104 cells/animal) after lethal irradiation. After 16 
weeks, animals were infected with LCMV-WE (200 pfu, i.p.). Animals 
were bled to assess serum IFN-γ levels at day 8 after infection and to per-
form complete blood counts on day 15 after infection.
Statistics. Statistical significance was determined by using unpaired, two-
tailed Student’s t-tests.
SUPPLEMENTARY MATERIAL
Figure S1.  GFP expression in different cell lines after transduction 92 
with PGK.PRF and PRF.PRF.
Figure S2.  Perforin expression and function in RBL-1 cells.
Figure S3. Lineage development in reconstituted mice is not 107 
affected by progenitor cell gene transfer.
Figure S4. Transgene expression in different organs following 113 
progenitor cell gene transfer.
Figure S5.  Lentiviral vector mediated HSC perforin gene transfer 117 
restores T and NK cell cytotoxic function and reduces IFN-γ secretion 
by T 118 lymphoblasts in vitro- experiment 1.
Figure S6.  Lentiviral vector mediated HSC perforin gene transfer 131 
restores T and NK cell cytotoxic function and reduces IFN-γ secretion 
by T 132 lymphoblasts in vitro- experiment 3.
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